Stefan Pierrou
Overview
Explore the profile of Stefan Pierrou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
425
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Modder M, In Het Panhuis W, Li M, Afkir S, Dorn A, Pronk A, et al.
Cardiovasc Res
. 2024 Sep;
120(17):2179-2190.
PMID: 39259836
Aims: Angiopoietin-like 3 (ANGPTL3) and 4 (ANGPTL4) inhibit lipoprotein lipase to regulate tissue fatty acid (FA) uptake from triglyceride (TG)-rich lipoproteins such as very low density lipoproteins (VLDL). While pharmacological...
2.
Velikyan I, Bossart M, Haack T, Laitinen I, Estrada S, Johansson L, et al.
Pharmaceuticals (Basel)
. 2023 Jan;
16(1).
PMID: 36678558
Imaging and radiotherapy targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR) could potentially benefit the management of neuroendocrine neoplasms (NENs), complementing clinically established radiopharmaceuticals. The aim of this study was to...
3.
Bossart M, Wagner M, Elvert R, Evers A, Hubschle T, Kloeckener T, et al.
Cell Metab
. 2021 Dec;
34(1):59-74.e10.
PMID: 34932984
Unimolecular triple incretins, combining the activity of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG), have demonstrated reduction in body weight and improved glucose control in rodent models....
4.
Eriksson O, Velikyan I, Haack T, Bossart M, Laitinen I, Larsen P, et al.
J Nucl Med
. 2021 Sep;
63(5):794-800.
PMID: 34503957
The glucagonlike peptide-1 receptor (GLP1R) is a gut hormone receptor, intricately linked to regulation of blood glucose homeostasis via several mechanisms. It is an established and emergent drug target in...
5.
Eriksson O, Velikyan I, Haack T, Bossart M, Evers A, Lorenz K, et al.
Diabetes
. 2021 Feb;
70(4):842-853.
PMID: 33547046
Targeting of the glucose-dependent insulinotropic polypeptide receptor (GIPR) is an emerging strategy in antidiabetic drug development. The aim of this study was to develop a positron emission tomography (PET) radioligand...
6.
Eriksson O, Velikyan I, Haack T, Bossart M, Laitinen I, Larsen P, et al.
J Nucl Med
. 2020 Oct;
62(6):833-838.
PMID: 33097629
Despite the importance of the glucagon receptor (GCGR) in disease and in pharmaceutical drug development, there is a lack of specific and sensitive biomarkers of its activation in humans. The...
7.
Eriksson O, Haack T, Hijazi Y, Teichert L, Tavernier V, Laitinen I, et al.
Sci Rep
. 2020 Oct;
10(1):16758.
PMID: 33028880
Unimolecular dual agonists for the glucagon-like peptide 1 receptor (GLP1R) and glucagon receptor (GCGR) are emerging as a potential new class of important therapeutics in type 2 diabetes (T2D). Reliable...
8.
Wagner M, Doverfjord J, Tillner J, Antoni G, Haack T, Bossart M, et al.
Pharmaceuticals (Basel)
. 2020 Aug;
13(8).
PMID: 32752075
: [Ga]Ga-DO3A-VS-Cys-Tuna-2 (previously published as [Ga]Ga-DO3A-VS-Cys-S01-GCG) has shown high-affinity specific binding to the glucagon receptor (GCGR) in vitro and in vivo in rats and non-human primates in our previous studies,...
9.
Eriksson O, Velikyan I, Haack T, Bossart M, Evers A, Laitinen I, et al.
Sci Rep
. 2019 Oct;
9(1):14960.
PMID: 31628379
The glucagon receptor (GCGR) is an emerging target in anti-diabetic therapy. Reliable biomarkers for in vivo activity on the GCGR, in the setting of dual glucagon-like peptide 1/glucagon (GLP-1/GCG) receptor...
10.
Velikyan I, Haack T, Bossart M, Evers A, Laitinen I, Larsen P, et al.
EJNMMI Res
. 2019 Feb;
9(1):17.
PMID: 30771019
Methods: Two potent GCG receptor peptide agonists, S01-GCG and S02-GCG, were labeled with positron emission tomography (PET) radionuclide gallium-68. The GCG receptor binding affinity and specificity of the resulting radiopharmaceuticals...